HFE p.C282Y (rs1800562) allele frequencies in 34 population/control cohorts in Iberia

Short title: *HFE* p.C282Y in Iberia

James C. Barton, M.D.[1,2*], J. Clayborn Barton, B.S.[1], and Ronald T. Acton, Ph.D.[1,3]

[1] Southern Iron Disorders Center, Birmingham, AL, USA

[2] Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA

[3] Department of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA

James C. Barton (corresponding author): bartonjames336@gmail.com; ORCID 0000-0003-2876-8276

J. Clayborn Barton: jbarton205@gmail.com; ORCID 0000-0002-2646-4466

Ronald T. Acton: rtakma@bellsouth.net; ORCID 0000-0002-8586-6887

Abstract

Background: *HFE* p.C282Y (c.845G>A; rs1800562) is a common missense mutation in persons of European ancestry, but we found no comprehensive tabulation of p.C282Y allele frequencies in Iberia.

Methods: We performed computerized and manual searches to identify evaluable reports of p.C282Y alleles in population/control cohorts ≥50 subjects in Iberia. We tabulated numbers of subjects, nominal geographic sites of cohort recruitment, cohort characteristics, corresponding latitudes and longitudes, and p.C282Y allele frequencies [95% confidence intervals]. We computed the aggregate p.C282Y allele frequencies of mainland Spain and mainland Portugal and compared the aggregate frequencies using the Chi-square test (two-tailed). Using combined mainland Spain and mainland Portugal data, we computed the aggregate p.C282Y allele frequency in Iberia.

Results: We identified 25 cohorts in mainland Spain (12,297 subjects; 11 of the 15 autonomous communities) and nine cohorts in mainland Portugal (1,024 subjects; each of the five administrative regions). Cohorts were recruited in this region: latitude 43.4619 – 37.2299° N; longitude -9.1366 – 2.1899° W. The range of p.C282Y allele frequencies in the 34 cohorts was 0.0000 to 0.0517. The aggregate p.C282Y allele frequency in mainland Spain was 0.0291 (716/24,594) [0.0271, 0.0313] and that in mainland Portugal was 0.0303 (62/2048) [0.0237, 0.0386] ($p = 0.8343$). The aggregate p.C282Y allele frequency in Iberia was 0.0292 (778/26,642) [0.0272, 0.0313].

Conclusions: We conclude that the aggregate *HFE* p.C282Y allele frequencies in mainland Spain and mainland Portugal do not differ significantly. The aggregate p.C282Y allele frequency of 34 population/control cohorts (13,321 subjects, 16 geographic regions) in Iberia is 0.0292.

Introduction

HFE, the homeostatic iron regulator (chromosome 6p22.2) [1,2], encodes the non-classical class I major histocompatibility complex protein HFE, an upstream modulator of the central iron-regulatory hormone hepcidin (*HAMP*, chromosome 19q13.12) [3]. *HFE* p.C282Y (c.845G>A; rs1800562) is a common missense mutation in persons of European ancestry [4,5]. p.C282Y homozygosity is associated with the predominant subtype of hemochromatosis [2,6].

Iberia, also known as the Iberian Peninsula, is a landmass of 583,544 km^2 (225,308 square miles) in southwestern Europe, which is separated from the rest of Europe by the Pyrenees Mountains [7]. The area of Iberia is predominantly that of mainland Spain (84.5%) and mainland Portugal (15.3%) [7]. The remaining area in the northeast comprises the microstate Andorra and a small part of the French department of Pyrénées-Orientales, and in the south, Gibraltar, a British Overseas Territory [7]. A comprehensive tabulation of the *HFE* p.C282Y allele frequencies of population/control cohorts in Iberia could be used to enhance knowledge of the geographic distribution of p.C282Y.

The aims of this study were 1) to identify all published reports of *HFE* p.C282Y allele frequencies in population/control cohorts in Iberia, 2) to tabulate the sizes, geographic locations, characteristics, and p.C282Y allele frequencies of the evaluable cohorts, and 3) to compute the aggregate p.C282Y allele frequency in Iberia. We discuss our findings and compare the aggregate p.C282Y allele frequency in Iberia with previously published p.C282Y allele frequencies in other regions of Europe.

Methods

Ethics statement

This study was performed according to the principles of the Declaration of Helsinki [8]. This study did not require institutional review board approval because the reports we identified were published previously and are publicly available, the report data contain no personally identifiable information, and the tabulation of the data does not permit re-identification of individuals [9].

Informed consent statement

Informed consent was not obtained because this study was based entirely on the discovery, review, tabulation, and analyses of published data that are publicly available and cannot be linked to individuals [9].

Definition of population/control cohort

We defined a population cohort as a group of research subjects who share a common characteristic(s) and are used in a study to represent the broader population. We defined a control cohort as a group of individuals in a study who do not have the condition or outcome of interest but who are otherwise similar to the individuals in the main study group and are presumed to represent the broader population. In this study, we defined population and control cohorts to be equivalent.

Literature searches for population/control cohorts

We performed computerized searches (using an internet browser with or without https://pubmed.ncbi.nlm.nih.gov/) to identify reports of *HFE* p.C282Y allele frequencies in

population/control cohorts in Iberia. We used *HFE* p.C282Y, rs1800562, and *HFE* mutation as search terms in combination with 1) names of countries, autonomous communities, administrative regions, and major cities, 2) disease-related terms including hemochromatosis, iron overload, cirrhosis, diabetes, arthritis, hepatitis, osteoporosis, porphyria cutanea tarda, leukemia, lymphoma, myeloma, cancer, and carcinoma, and 3) the terms *HFE* p.H63D (rs1799945) and *HFE* p.S65C (rs1800730). We manually searched the references cited in reports identified by computerized searches.

Definition of evaluable population/control cohorts

We defined evaluable cohorts as ones in which the corresponding reports included all of the following data: 1) 50 or more population/control subjects [10]; 2) the nominal geographic site of subject recruitment (or location of the primary investigator's institution, as appropriate); 3) the characteristics of the subjects; and 4) determinable numbers of *HFE* p.C282Y and total alleles.

Population/control cohorts excluded

We did not tabulate data from reports that described the following: 1) Roma people and other Iberian residents who were not regarded as Iberian natives by the corresponding investigators; 2) no geographic location of cohort recruitment other than country; 3) *HFE* p.C282Y allele frequencies estimated using population prevalences of p.C282Y homozygotes; and 4) the publication of a previously reported population/control cohort. We excluded cohorts from the Balearic and Canary Islands (Spain), the Azores and Madeira (Portugal), and the autonomous cities of Ceuta and Melilla in Northern Africa (Spain) because these geographic regions are not in Iberia [7].

Data tabulation

We tabulated these data of the evaluable population/control cohorts: 1) the numbers of subjects; 2) the nominal geographic sites of the recruitment of subjects (or the locations of primary investigator institutions, as appropriate); 3) the characteristics of the cohorts; 4) the latitudes and longitudes in decimal degrees (four decimal places) [11] of the geographic sites of recruitment; and 5) the corresponding *HFE* p.C282Y allele frequencies.

Statistics

All data are displayed herein and in the corresponding literature citations. We computed the *HFE* p.C282Y allele frequency for each cohort as the quotient of (number of p.C282Y alleles) by (number of subjects x 2), expressed to four decimal places [95% confidence interval]. We computed the aggregate p.C282Y allele frequencies for mainland Spain and mainland Portugal in a similar manner and compared them using the Chi-square test (two-tailed). We defined allele frequencies from mainland Spain and mainland Portugal as representative of Iberia and likewise computed the aggregate p.C282Y allele frequency for Iberia. We used Excel® 2000 (Microsoft Corp., Redmond, WA, USA) and GraphPad Prism 8® (2018; GraphPad Software, San Diego, CA, USA). We defined $p < 0.05$ as significant.

Results

Mainland Spain

We identified 25 evaluable population/control cohorts (12,297 subjects) from these 11 autonomous communities of mainland Spain: Aragon, Asturias, Basque Country, Cantabria, Castile-La Mancha, Catalonia, Extremadura, Galicia, Madrid, Murcia, and Valencia (Table 1). The range of subjects per cohort was 50 to 5,370 (Table 1). Cohorts were recruited in this region: latitude 43.4619 – 37.9924° N; longitude -8.5459 – 2.1771° W (Table 1). The range of *HFE* p.C282Y allele frequencies was 0.0068 (Murcia/Murcia) to 0.0517 (Basque Country/Guipuzcoa) (Table 1).

We did not discover reports of evaluable population/control cohorts from these four autonomous communities of north-central and south-central mainland Spain: Andalusia, Castile and León, La Rioja, and Navarre.

Table 1. *HFE* p.C282Y allele frequencies in 12,082 population/control subjects in mainland Spain

Subjects, n	Autonomous community/ province or city	Latitude° N	Longitude° W	p.C282Y/ total alleles	p.C282Y allele frequency [95% confidence interval]	Author (Year) [reference]
215	Aragon/Zaragoza[1]	41.6521	-0.8809	430	0.0372 [0.0230, 0.0596]	Solanos-Barca (2009) [12]
159	Asturias/Oviedo[2]	43.3619	-5.8484	11/318	0.0346 [0.0194, 0.0609]	Lauret (2002) [13]
51	Basque Country[3]	42.9912	-2.5543	2/102	0.0196 [0.0054, 0.0687]	Baiget (1998) [14]
116	Basque Country/Guipuzcoa [4]	43.1445	-2.2038	12/232	0.0517 [0.0298, 0.0882]	de Juan (2001) [15][5]
281	Basque Country/Barakaldo[6]	43.2955	-2.9901	12/562	0.0214 [0.0123, 0.0370]	de Buruaga (2023) [17]
213	Cantabria/Santander[7]	43.4619	-3.8100	19/426	0.0446 [0.0287, 0.0686]	Fábrega (2004) [18]
150	Castile-La Mancha/Toledo[8]	39.8559	-4.0243	9/300	0.0300 [0.0159, 0.0560]	de Diego (2004) [19]
50	Catalonia[9]	41.8523	1.5745	3/100	0.0300 [0.0103, 0.0845]	Merryweather-Clarke (1997) [4]
348	Catalonia[10]	41.8523	1.5745	21/696	0.0302 [0.0198, 0.0457]	Berez (2005) [20]
108	Catalonia/Barcelona[11]	41.3826	2.1771	8/216	0.0370 [0.0189, 0.0713]	Baiget (1998) [14][12]
512	Catalonia/Barcelona[13]	41.3826	2.1771	31/1024	0.0303 [0.0214, 0.0427]	Sánchez (1998) [22]
5370	Catalonia/Barcelona[14]	41.3826	2.1771	339/10740	0.0316 [0.0285, 0.0351]	Sánchez (2003) [23]
1043	Catalonia/Barcelona[15]	41.3826	2.1771	61/2086	0.0292 [0.0228, 0.0373]	Altes (2004) [24]
126	Catalonia/Barcelona[16]	41.3826	2.1771	7/252	0.0278 [0.0135, 0.0562]	Toll (2006) [25]

[1] normolipemic subjects
[2] healthy bone marrow donors
[3] not otherwise specified
[4] provincial blood donors with Basque surnames
[5] Castiella et al. (2010) published similar data [16].
[6] controls with gout (n = 128), osteoarthritis (n = 102), and rheumatoid arthritis (n = 70) without chondrocalcinosis, calcium pyrophosphate crystals in synovial fluid, hemochromatosis, or primary hyperparathyroidism
[7] provincial blood donors
[8] randomly selected healthy subjects without iron overload
[9] anthropological community-based survey
[10] randomly selected subjects from population registries in two villages
[11] voluntary blood donors
[12] Fernndez-Real et al. (1999) [21] and Gimferrer et al. (1999) [14] published similar data.
[13] voluntary blood donors and paternity testing clients
[14] voluntary blood donors
[15] randomly selected newborn screening cards
[16] randomly selected laboratory subjects (76 healthy + 50 with chronic hepatitis C without a history of porphyria cutanea tarda or hemochromatosis)

812	Catalonia/Tarragona[17]	41.1172	1.2546	50/1624	0.0308 [0.0234, 0.0404]	Aranda (2007) [26][18]
179	Extremadura/Badajoz[19]	38.8782	-6.9701	16/358	0.0447 [0.0277, 0.0714]	Rodríguez-López (2012) [28]
125	Extremadura/Cáceres[20]	39.5152	-6.4506	5/250	0.0200 [0.0086, 0.0460]	Alvarez (2001) [29]
50	Galicia/Santiago de Compostela[21]	42.8804	-8.5459	5/100	0.0500 [0.0215, 0.1118]	Soto (2000) [30]
50	Madrid/Madrid[22]	40.4583	-3.7727	2/100	0.0200 [0.0055, 0.0700]	de Salamanca[23] (1999) [32]
174	Madrid/Madrid[24]	40.4583	-3.7727	8/348	0.0230 [0.0117, 0.0447]	Moreno (1999) [33]
150	Madrid/Madrid[25]	40.4583	-3.7727	9/300	0.0300 [0.0159, 0.0560]	Gonzalez-Hevilla (2005) [34]
551	Madrid/Madrid[26]	40.4583	-3.7727	25/1102	0.0227 [0.0154, 0.0333]	Ropero-Gradilla (2005) [35]
1000	Madrid/Madrid[27]	40.4583	-3.7727	33/2000	0.0165 [0.0118, 0.0231]	Ropero (2006) [36]
370	Murcia/Murcia[28]	37.9924	-1.1305	5/740	0.0068 [0.0029, 0.0158]	Muro (2007) [37]
94	Valencia/Valencia[29]	39.4697	-0.3763	7/188	0.0372 [0.0181, 0.0748]	Monzó (2017) [38]

[17] randomly selected from the electoral rolls of three municipalities in Tarragona
[18] Aranda et al. (2010) published similar data [27].
[19] unrelated gender-matched healthy individuals
[20] voluntary unrelated blood donors
[21] random samples representative of the Galician population
[22] unrelated healthy subjects
[23] Ramirez et al. (2009) reported similar data [31].
[24] randomly selected subjects
[25] normal subjects
[26] cord blood leukocytes
[27] neonates
[28] unrelated white Spanish blood donors
[29] random healthy subjects

Mainland Portugal

We identified nine evaluable population/control cohorts (1,024 subjects) from the five administrative regions of mainland Portugal: Alentejo, Algarve, Centro, Lisbon-Tagus Valley, and Norte (Table 2). The range of subjects per cohort was 52 to 146 (Table 2). Cohorts were recruited in this region: latitude 41.4563 – 37.2299° N; longitude -9.1366 – -7.4817° W (Table 2). The range of *HFE* p.C282Y allele frequencies was 0.000 to 0.0581 (Table 2).

Table 2. *HFE* p.C282Y allele frequencies in 1,024 population/control subjects in mainland Portugal

Subjects, n	**Administrative Region[a]/city**	**Latitude° N**	**Longitude° W**	**p.C282Y/ total alleles**	**p.C282Y allele frequency [95% confidence interval]**	**Author (Year) [reference]**
132	Alentejo[30]	38.0551	-7.8606	6/264	0.0227 [0.0104, 0.0487]	Cardoso (2001) [39]
116	Algarve[29]	37.2299	-7.4817	2/232	0.0086 [0.0024, 0.0308]	Cardoso (2001) [39]
130	Centro[29]	39.9802	-7.9056	12/260	0.0462 [0.0266, 0.0790]	Cardoso (2001) [39]
115	Centro/Coimbra[31]	40.2112	-8.4295	5/230	0.0217 [0.0093, 0.0498]	Guerreiro (2006) [40]
52	Centro/Viseu[32]	40.6575	-7.9139	0/104	0.0000 [0, 0.0356]	Costo-Matos (2013) [41]
133	Lisbon-Tagus Valley[29]	38.7078	-9.1366	8/266	0.0301 [0.0153, 0.0582]	Cardoso (2001) [39][33]
129	Norte[29]	41.4563	-7.5387	15/258	0.0581 [0.0355, 0.0936]	Cardoso (2001) [39]
71	Norte/Porto[34]	41.1502	-8.6104	4/142	0.0282 [0.0010, 0.0702]	Porto (1998) [43]
146	Norte/Porto[35]	41.1502	-8.6104	10/292	0.0342 [0.0187, 0.0618]	Cardoso (2006) [44][36]

[a] Administrative Regions (and their secondary divisions) are: Alentejo (Beja, Évora, and Portalegre); Algarve (Faro); Centro (Aveiro, Castelo Branco, Coimbra, Guarda, Leiria, and Viseu); Lisbon-Tagus Valley (Lisboa**,** Santarém, and Setúbal); and Norte (Braga, Bragança, Porto, Vila Real, and Viana do Castelo).

Other regions of Iberia

We did not discover reports of evaluable population/control cohorts from Andorra, Pyrénées-Orientales, or Gibraltar.

[30] from a stratified random sample of anonymous dried blood spot samples from newborns
[31] healthy controls free of clinical signs or symptoms of neurodegeneration
[32] healthy controls (during elective cholecystectomy)
[33] Machado et al. (2009) published similar data [42].
[34] unrelated apparently healthy subjects
[35] apparently healthy control population of women
[36] Bettencourt et al. (2011) published similar data [45].

Aggregate HFE p.C282Y allele frequencies

The aggregate p.C282Y allele frequency in mainland Spain was 0.0291 (716/24,594) [0.0271, 0.0313] (Table 1). The aggregate p.C282Y allele frequency in mainland Portugal was 0.0303 (62/2048) [0.0237, 0.0386] (Table 2). These frequencies did not differ significantly ($p = 0.8343$). The aggregate p.C282Y allele frequency in Iberia was 0.0292 (778/26,642) [0.0272, 0.0313].

Discussion

Novel findings of this tabulation of *HFE* p.C282Y allele frequencies in Iberia are 1) the large number of evaluable population/control cohorts we discovered and 2) the wide range of p.C282Y allele frequencies across geographic regions. The present aggregate p.C282Y allele frequency percentage in Iberia (2.9) is lower than the p.C282Y allele frequency percentages reported from Ireland (9.7, 10.0), Wales (8.2), Brittany (7.7), Scotland (7.7), England (6.0, 7.7), and Norway (6.4, 6.6), and higher than the p.C282Y frequency percentages reported from Greece (1.0, 1.4) and Italy (0.5, 1.7) [4,5]. The present tabulation of p.C282Y allele frequencies in 34 Iberian cohorts (13,321 subjects, 16 geographic regions) could be used to enhance knowledge of the distribution of p.C282Y in Iberia and Europe.

Uncertainties of this study include the possibilities that: 1) we overlooked one or more published reports of evaluable population/control cohorts; 2) the same subjects were included in more than one cohort or report; and 3) some cohorts were not representative of their respective geographic regions due to the site(s) or method(s) of subject recruitment or to inadequate cohort size, especially in geographic regions with low *HFE* p.C282Y allele frequencies. A limitation of this study is that we discovered no reports of evaluable population/control cohorts from five autonomous communities of mainland Spain or from Andorra, Pyrénées-Orientales, or Gibraltar. Analyzing the relationships of the present p.C282Y allele frequencies with their geographic locations in Iberia or with regional prevalences of hemochromatosis associated with p.C282Y homozygosity was beyond the scope of this study.

Conclusions

We conclude that the aggregate *HFE* p.C282Y allele frequencies in mainland Spain and mainland Portugal do not differ significantly. The aggregate p.C282Y allele frequency of 34 population/control cohorts (13,316 subjects, 16 geographic regions) in Iberia is 0.0292.

Authors' contributions

Each author contributed substantively to this study. JaCB conceived this study and its methodology, curated data, evaluated reports from the literature, performed analyses, and drafted the manuscript. JClB curated data, evaluated reports from the literature, performed analyses, and drafted the manuscript. RTA curated data, evaluated reports from the literature, contributed to study methodology, performed analyses, and drafted the manuscript. Each author approved the manuscript in its final form.

Competing interest statement

The authors report no conflict of interest.

Funding statement

The authors received funding from the Southern Iron Disorders Center.

Data Sharing Statement

All data used in the present study are either displayed herein or in the corresponding literature citations.

References

1. Barton JC, Edwards CQ, Acton RT. *HFE* gene: Structure, function, mutations, and associated iron abnormalities. Gene. 2015;574: 179-192. doi: 10.1016/j.gene.2015.10.009

2. Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU, et al. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood. 2022;139: 3018-3029. doi: 10.1182/blood.2021011338

3. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117: 4425-4433. doi: 10.1182/blood-2011-01-258467

4. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34: 275-278. doi: 10.1136/jmg.34.4.275

5. Milman N, Pedersen P. Evidence that the Cys282Tyr mutation of the *HFE* gene originated from a population in Southern Scandinavia and spread with the Vikings. Clin Genet. 2003;64: 36-47. doi: 10.1034/j.1399-0004.2003.00083.x

6. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13: 399-408. doi: 10.1038/ng0896-399

7. Wikipedia. Iberian Peninsula. https://en.wikipedia.org/wiki/Iberian_Peninsula. Last updated November 29, 2025. Accessed December 1, 2025.

8. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310: 2191-2194. doi: 10.1001/jama.2013.281053

9. National Archives and Records Administration. Code of Federal Regulations. §46.104 Exempt Research. https://www.ecfr.gov/current/title-45/section-46.104. Last updated May 5, 2025. Accessed June 21, 2025.

10. Hale ML, Burg TM, Steeves TE. Sampling for microsatellite-based population genetic studies: 25 to 30 individuals per population is enough to accurately estimate allele frequencies. PLoS One. 2012;7: e45170. doi: 10.1371/journal.pone.0045170

11. prodigital.at IT Services. mapcoordinates.net. https://www.mapcoordinates.net/. Last updated January 1, 2025. Accessed June 13, 2025.

12. Solanas-Barca M, Mateo-Gallego R, Calmarza P, Jarauta E, Bea AM, et al. Mutations in *HFE* causing hemochromatosis are associated with primary hypertriglyceridemia. J Clin Endocrinol Metab. 2009;94: 4391-4397. doi: 10.1210/jc.2009-0814

13. Lauret E, Rodrguez M, González S, López-Vázquez A, Martinez-Borra J, et al. *HFE* gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol. 2002;97: 1016-1021. doi: 10.1111/j.1572-0241.2002.05553.x

14. Baiget M, Barceló MJ, Gimferrer E. Frequency of the *HFE* C282Y and H63D mutations in distinct ethnic groups living in Spain. J Med Genet. 1998;35: 701. doi: 10.1136/jmg.35.8.701

15. de Juan D, Reta A, Castiella A, Pozueta J, Prada A, et al. *HFE* gene mutations analysis in Basque hereditary haemochromatosis patients and controls. Eur J Hum Genet. 2001;9: 961-964. doi: 10.1038/sj.ejhg.5200731

16. Castiella A, Zapata E, de Juan MD, Otazua P, Fernandez J, et al. Significance of H63D homozygosity in a Basque population with hemochromatosis. J Gastroenterol Hepatol. 2010;25: 1295-1298. doi: 10.1111/j.1440-1746.2010.06247.x

17. de Buruaga JAS, Perez-Herrero N, Perez-Herrero N, Vazquez-Puente C, del Consuelo Modesto-Caballero M, et al. Association of mutations in hemochromatosis genes with clinical severity of calcium pyrophosphate arthritis. Explor Musculoskeletal Dis. 2023;1: 186-193. doi: 10.37349/emd.2023.00021

18. Fábrega E, Castro B, Sánchez-Castro L, Benito A, Fernández-Luna JL, et al. [The prevalence of the Cys282Tyr mutation in the hemochromatosis gene in Cantabria in patients diagnosed with hereditary hemochromatosis]. Med Clin (Barc). 1999;112: 451-453

19. de Diego C, Murga MJ, Martínez-Castro P. Frequency of *HFE* H63D, S65C, and C282Y mutations in patients with iron overload and controls from Toledo, Spain. Genet Test. 2004;8: 263-267. doi: 10.1089/gte.2004.8.263

20. Berez V, Camps J, Arija V, Aranda N, Fernández-Ballart J, et al. Soluble transferrin receptor and mutations in hemochromatosis and transferrin genes in a general Catalan population. Clin Chim Acta. 2005;353: 205-208. doi: 10.1016/j.cccn.2004.10.020

21. Fernandez-Real JM, Vendrell J, Baiget M, Gimferrer E, Ricart W. C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes. Diabetes Care. 1999;22: 525-526. doi: 10.2337/diacare.22.3.525

22. Sánchez M, Bruguera M, Bosch J, Rodés J, Ballesta F, et al. Prevalence of the Cys282Tyr and His63Asp *HFE* gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol. 1998;29: 725-728. doi: 10.1016/s0168-8278(98)80252-3

23. Sánchez M, Villa M, Ingelmo M, Sanz C, Bruguera M, et al. Population screening for hemochromatosis: a study in 5370 Spanish blood donors. J Hepatol. 2003;38: 745-750. doi: 10.1016/s0168-8278(03)00123-5

24. Altes A, Ruiz A, Barceló MJ, Remacha AF, Puig T, et al. Prevalence of the C282Y, H63D, and S65C mutations of the *HFE* gene in 1,146 newborns from a region of Northern Spain. Genet Test. 2004;8: 407-410. doi: 10.1089/gte.2004.8.407

25. Toll A, Celis R, Ozalla MD, Bruguera M, Herrero C, et al. The prevalence of *HFE* C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection. J Eur Acad Dermatol Venereol. 2006;20: 1201-1206. doi: 10.1111/j.1468-3083.2006.01746.x

26. Aranda N, Viteri FE, Fernandez-Ballart J, Murphy M, Arija V. Frequency of the hemochromatosis gene (*HFE*) 282C-->Y, 63H-->D, and 65S-->C mutations in a general Mediterranean population from Tarragona, Spain. Ann Hematol. 2007;86: 17-21. doi: 10.1007/s00277-006-0179-0

27. Aranda N, Viteri FE, Montserrat C, Arija V. Effects of C282Y, H63D, and S65C *HFE* gene mutations, diet, and life-style factors on iron status in a general Mediterranean population from Tarragona, Spain. Ann Hematol. 2010;89: 767-773. doi: 10.1007/s00277-010-0901-9

28. Rodríguez-López R, Donoso M, Fernández-Cavada M, González LM, Margallo A, et al. Diagnostic utility of *HFE* variants in Spanish patients: association with HLA alleles and role in susceptibility to acute lymphoblastic leukemia. Gene. 2013;514: 31-35. doi: 10.1016/j.gene.2012.10.090

29. Alvarez S, Mesa MS, Bandrés F, Arroyo E. C282Y and H63D mutation frequencies in a population from central Spain. Dis Markers. 2001;17: 111-114. doi: 10.1155/2001/350460

30. Soto L, Vega A, Goyanes V, Valverde D. Hemochromatosis in Galicia (nw Spain): a Celtic influence? Clin Genet. 2000;57: 454-455. doi: 10.1034/j.1399-0004.2000.570610.x

31. Ramirez E, Pacho A, Morales JM, De C, I, Paz-Artal E, et al. Frequency and influence of hemochromatosis gene mutations in kidney transplant recipients with or without hepatitis C virus infection. Transplant Proc. 2009;41: 2422-2424. doi: 10.1016/j.transproceed.2009.06.021

32. de Salamanca RE, Morales P, Castro MJ, Rojo R, Gonzalez M, et al. The most frequent *HFE* allele linked to porphyria cutanea tarda in Mediterraneans is His63Asp. Hepatology. 1999;30: 819-820. doi: 10.1002/hep.510300320

33. Moreno L, Vallcorba P, Boixeda D, Cabello P, Bermejo F, et al. [The usefulness of the detection of Cys282Tyr and His63Asp mutations in the diagnosis of hereditary hemochromatosis]. Rev Clin Esp. 1999;199: 632-636

34. Gonzalez-Hevilla M, de Salamanca RE, Morales P, Martinez-Laso J, Fontanellas A, et al. Human leukocyte antigen haplotypes and *HFE* mutations in Spanish hereditary hemochromatosis and sporadic porphyria cutanea tarda. J Gastroenterol Hepatol. 2005;20: 456-462. doi: 10.1111/j.1440-1746.2005.03553.x

35. Ropero-Gradilla P, Gonzalez-Fernández FA, Briceño-Polacre O, Villegas-Martinez A. [Geographical distribution of *HFE* C282Y and H63D mutation in Spain]. Med Clin (Barc). 2005;125: 794-795. doi: 10.1016/s0025-7753(05)72193-x

36. Ropero P, Briceño O, Mateo M, Polo M, Mora A, et al. Frequency of the C282Y and H63D mutations of the hemochromatosis gene (*HFE*) in a cohort of 1,000 neonates in Madrid (Spain). Ann Hematol. 2006;85: 323-326. doi: 10.1007/s00277-006-0094-4

37. Muro M, Moya-Quiles MR, Botella C, Álvarez-López MR. Prevalence of C282Y, H63D and S65C mutations of the hemochromatosis (*HFE*) gene in a population from southeastern Spain (Murcia Region). Clin Genet. 2007;71: 97-98. doi: 10.1111/j.1399-0004.2006.00730.x

38. Monzó C, Ortiz B, Tomás C, Collado C, González-Muñoz C, et al. Different distribution of the common *HFE* variants between western and eastern Spanish populations evidences an independent haplotype gene flow. Rev Lab Clin. 2017;10: 72-78. doi: 10.1016/j.labcli.2016.12.003

39. Cardoso CS, Oliveira P, Porto G, Oberkanins C, Mascarenhas M, et al. Comparative study of the two more frequent *HFE* mutations (C282Y and H63D): significant different allelic frequencies between the North and South of Portugal. Eur J Hum Genet. 2001;9: 843-848. doi: 10.1038/sj.ejhg.5200723

40. Guerreiro RJ, Bras JM, Santana I, Januario C, Santiago B, et al. Association of *HFE* common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 2006;6: 24. doi: 10.1186/1471-2377-6-24

41. Costa-Matos L, Batista P, Monteiro N, Henriques P, Girão F, et al. *Hfe* mutations and iron overload in patients with alcoholic liver disease. Arq Gastroenterol. 2013;50: 35-41. doi: 10.1590/s0004-28032013000100008

42. Machado MV, Ravasco P, Martins A, Almeida MR, Camilo ME, et al. Iron homeostasis and H63D mutations in alcoholics with and without liver disease. World J Gastroenterol. 2009;15: 106-111. doi: 10.3748/wjg.15.106

43. Porto G, Alves H, Rodrigues P, Cabeda JM, Portal C, et al. Major histocompatibility complex class I associations in iron overload: evidence for a new link between the *HFE* H63D mutation, HLA-A29, and non-classical forms of hemochromatosis. Immunogenetics. 1998;47: 404-410. doi: 10.1007/s002510050376

44. Cardoso CS, Araújo HC, Cruz E, Afonso A, Mascarenhas C, et al. Haemochromatosis gene (*HFE*) mutations in viral-associated neoplasia: Linkage to cervical cancer. Biochem Biophys Res Commun. 2006;341: 232-238. doi: 10.1016/j.bbrc.2005.12.174

45. Bettencourt A, Silva AM, Santos E, Gomes S, Mendonça D, et al. *HFE* gene polymorphisms and severity in Portuguese patients with multiple sclerosis. Eur J Neurol. 2011;18: 663-666. doi: 10.1111/j.1468-1331.2010.03109.x